Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Genetic study of non-Langerhans cell histiocytosis

PROVIDER: PRJNA690872 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13389900_1.fastq.gz	Fastqsanger.gz
	SRR13389900_2.fastq.gz	Fastqsanger.gz
	SRR13389901_1.fastq.gz	Fastqsanger.gz
	SRR13389901_2.fastq.gz	Fastqsanger.gz
	SRR13389902_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 144

Similar Datasets

Project description:Genetic study of adult Langerhans cell histiocytosis

| PRJNA672227 | ENA

Project description:Genetic study of adult Langerhans cell histiocytosis (germline control)

| PRJNA672228 | ENA

Project description:Genetic study in adult patients with Langerhans cell histiocytosis

| PRJNA1155318 | ENA

Project description:Genetic Landscape of Adult Langerhans Cell Histiocytosis

| PRJNA533741 | ENA

Notch is active in Langerhans Cell Histiocytosis and confers pathognomonic features on dendritic cells.

Project description:Langerhans cell histiocytosis (LCH) is a disease characterized by the accumulation of eponymous CD1a+ Langerin+ Langerhans-cell (LC)-like dendritic cells (DC) of largely unknown origin. Here we have performed comparative transcriptome analysis of highly purified CD207+/CD1a+ Langerhans cell histiocytosis (LCH) cells derived from different locations and disease courses and three major human dendritic cell lineages: epidermal Langerhans cells, myeloid dendritic cells (mDC1) and plasmacytoid dendritic cells (pDC) in order to investigate the relationship between LCH cells and naturally occurring dendritic cells. Data obtained indicate that LCH cells form a distinct DC entity. Furthermore, we have identified transcripts that are uniquely expressed by LCH cells in comparison to LC, mDC1, and pDC, and induce LCH-specific features in human DC. Primary cells were isolated from peripheral blood (mDC1 and pDC), skin (epidermal Langerhans cells) and CD207+/CD1a+ Langerhans cell histiocytosis (LCH) cells derived from different locations. RNA was isolated from these cells ex vivo.

2012-10-24 | E-GEOD-35340 | biostudies-arrayexpress

JAG2 signaling induces differentiation of CD14+ monocytes into Langerhans Cell Histiocytosis-like cells

Project description:This study aims to identify the cell of origin of Langerhans Cell Histiocytosis and the molecular mechanisms of its pathogenesis.

2018-07-29 | GSE114181 | GEO

Notch is active in Langerhans Cell Histiocytosis and confers pathognomonic features on dendritic cells.

2012-10-24 | GSE35340 | GEO

Homo sapiens

Project description:Cell-Specific Gene Expression in Langerhans Cell Histiocytosis

| PRJNA116283 | ENA

ena-DATASET-RUMC-23-08-2015-11:30:21:063-53 - samples

Project description:Whole Exome Sequencing data from the germline of the patient as well as the tumors in bone marrow (T-ALL), Liver (Histiocytic Sarcoma) and ileum (non-Langerhans Cell Histiocytosis).

| EGAD00001001596 | EGA

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Project description:Histiocytic neoplasms are clonal, hematopoietic disorders characterized by an accumulation of abnormal, monocyte-derived dendritic cells or macrophages in Langerhans Cell (LCH) and non-Langerhans (non-LCH) histiocytoses, respectively. The discovery of BRAFV600E mutations in ~50% of these patients provided the first molecular therapeutic target in histiocytosis. However, recurrent driving mutations in the majority of BRAFV600E-wildtype, non-LCH patients are unknown, and recurrent cooperating mutations in non-MAP kinase pathways are undefined for the histiocytic neoplasms. Through combined whole exome and transcriptome sequencing, we identified recurrent kinase fusions involving BRAF, ALK, and NTRK1, as well as recurrent, activating MAP2K1 and ARAF mutations in BRAFV600E-wildtype, non-LCH patients. In addition to MAP kinase pathway lesions, recurrently altered genes involving diverse cellular pathways were identified. Treatment of MAP2K1- and ARAF-mutated, non-LCH patients using MEK and RAF inhibitors, respectively, resulted in clinical efficacy demonstrating the importance of detecting and targeting diverse kinase alterations in these disorders. 13 patient samples were analyzed by RNA-seq and had 2 replicates.

2015-11-11 | E-GEOD-74442 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data